Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Oseltamivir Carboxylate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oseltamivir Carboxylate SCHEMBL13968374 | 0.95 | — | — | |
| Oseltamivir Carboxylate SCHEMBL12820854 | 0.95 | — | — | |
| Oseltamivir Carboxylate SCHEMBL1977050 | 0.95 | — | — | |
| Oseltamivir Carboxylate SCHEMBL28431271 | 0.95 | — | — | |
| Oseltamivir Carboxylate SCHEMBL4563861 | 0.95 | — | — | |
| Oseltamivir Carboxylate SCHEMBL14080012 | 0.95 | — | — | |
| Oseltamivir Carboxylate SCHEMBL182903 | 0.95 | — | — | |
| Oseltamivir Carboxylate SCHEMBL17889878 | 0.95 | — | — | |
| Oseltamivir Carboxylate SCHEMBL20607528 | 0.95 | — | — | |
| Oseltamivir Carboxylate SCHEMBL28438495 | 0.95 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1606242-B1 | AZIDE FREE PROCESS FOR PREPARING 1,2-DIAMINO COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2007-03-14 | — | — | EP | claimed |
| US-7122684-B2 | Process for preparing 1,2-diamino compounds | ROCHE COLORADO CORPORATION (US) | 2006-10-17 | — | — | US | claimed |
| EP-1606242-A1 | AZIDE FREE PROCESS FOR PREPARING 1,2-DIAMINO COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-12-21 | — | — | EP | claimed |
| WO-2004080944-A1 | AZIDE FREE PROCESS FOR PREPARING 1,2-DIAMINO COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-09-23 | — | — | WO | claimed |
| US-20040180933-A1 | Process for preparing 1,2-diamino compounds | ROCHE PALO ALTO LLC | 2004-09-16 | — | — | US | claimed |
| US-10919856-B2 | Cyclohexene compounds and use thereof | GUANGZHOU HENOVCOM BIOSCIENCE CO. LTD. (CN) | 2021-02-16 | — | — | US | disclosed |
| US-20190241520-A1 | CYCLOHEXENE COMPOUNDS AND USE THEREOF | GUANGZHOU HENOVCOM BIOSCIENCE CO. LTD. (CN) | 2019-08-08 | — | — | US | disclosed |
| EP-1987825-B1 | PHARMACEUTICAL COMPOSITION COMPRISING OSELTAMIVIR PHOSPHATE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2018-09-05 | — | — | EP | disclosed |
| EP-2190439-B1 | OSELTAMIVIR PHOSPHONATE DERIVATIVES WITH ANTI-INFLUENZA ACTIVITY AND SYNTHESIS THEREOF | ACADEMIA SINICA (TW) | 2016-03-09 | — | — | EP | disclosed |
| US-9012499-B2 | Pharmaceutical composition comprising oseltamivir phosphate | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-04-21 | — | — | US | disclosed |
| WO-2015011282-A2 | METHOD FOR IDENTIFYING MODULATORS OF ABC TRANSPORTER-MEDIATED ATP RELEASE AND USE OF SAID MODULATORS FOR TREATING DISEASES | ENERGEIA BIOSCIENCES B.V. GbR No. 321 (NL) | 2015-01-29 | — | — | WO | disclosed |
| US-20100222427-A1 | PHARMACEUTICAL COMPOSITION COMPRISING OSELTAMIVIR PHOSPHATE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-09-02 | — | — | US | disclosed |
| US-7122684-B2 | Process for preparing 1,2-diamino compounds | ROCHE COLORADO CORPORATION (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1127872-B1 | Tamiflu via Diels-Alder | HOFFMANN LA ROCHE (CH) | 2006-02-01 | — | — | EP | disclosed |
| EP-1606242-A1 | AZIDE FREE PROCESS FOR PREPARING 1,2-DIAMINO COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004080944-A1 | AZIDE FREE PROCESS FOR PREPARING 1,2-DIAMINO COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-09-23 | — | — | WO | disclosed |
| US-20040180933-A1 | Process for preparing 1,2-diamino compounds | ROCHE PALO ALTO LLC | 2004-09-16 | — | — | US | disclosed |
| US-6403824-B2 | NEURAMINIDASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2002-06-11 | — | — | US | disclosed |
| US-20020006960-A1 | Process for the preparation fo 4,5-diamino shikimic acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-17 | — | — | US | disclosed |
| EP-1127872-A1 | Tamiflu via Diels-Alder | F. HOFFMANN-LA ROCHE AG (CH) | 2001-08-29 | — | — | EP | disclosed |